Table 2.

Predictors of failure/relapse in original Study 22 data and in EOT CXR data^*

	Original Study 22 data (n = 1004)		EOT CXR data (n = 834)
Variable	Univariate HR (95%CI)	Multivariable HR (95%CI)	Univariate HR (95%CI)	Multivariable HR (95%CI)
Treatment arm	1.86 (1.09–3.16)	NA	1.86 (1.09–3.16)	NA
Positive 2-month sputum culture	4.73 (2.85–7.85)	2.80 (1.64–4.77)	4.73 (2.85–7.85)	2.61 (1.52–4.47)
Cavity on CXR
None	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Cavity on early CXR	4.55 (2.31–8.96)	2.97 (1.48–5.96)	— †	— †
Cavity on early CXR, resolved	— †	— †	3.01 (1.42–6.40)	2.19 (1.02–4.71)
Persistent cavity on EOT CXR	— †	— †	7.23 (3.52–14.85)	4.22 (2.00–8.91)‡
White race	2.53 (1.49–4.31)	1.89 (1.10–3.25)	2.53 (1.49–4.31)	1.84 (1.07–3.17)
Underweight	4.13 (2.44–6.98)	2.97 (1.74–5.06)	4.13 (2.44–6.98)	2.92 (1.71–4.99)
Bilateral disease (2-month)	2.90 (1.57–5.36)	NA	2.90 (1.57–5.36)	NA
Bilateral disease (EOT CXR)	— †	— †	2.79 (1.66–4.69)	NA

^*EOT CXR data excludes treatment failure cases and missing CXR or culture data.

^†Analyses not done.

^‡P value = 0.02 for comparison of subjects with cavity on early CXR vs. subjects with persistent cavity on CXR.

EOT = end of treatment; CXR = chest radiograph; HR = hazard ratio; CI = confidence interval; NA = not available; TB = tuberculosis.